Source
Division of Nephrology, Division of Gastroenterology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Department of Pathology, Veterans General Hospital-Taipei, and Department of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract
Interferon is used to treat chronic viral hepatitis because of low drug resistance and a high remission rate. However, its propensity to induce and modify autoimmunity has been reported. We used pegylated interferon ?-2a to treat a patient with chronic viral hepatitis B. After 5 months of this therapy, the patient developed membranous nephropathy. Complete remission of his nephrotic syndrome was achieved after 1 year of cyclosporine and corticosteroid therapy. During this same period, his chronic viral hepatitis B was controlled by entecavir. To our knowledge, this is the first case in which membranous nephropathy developed during pegylated interferon ?-2a therapy for chronic hepatitis B. The autoimmune modulation induced by interferon is the most likely mechanism for this complication.
Clin Nephrol.
2012 Jun;77(6):496-500.
Membranous nephropathy induced by pegylated interferon alpha-2a therapy for chronic viral hepatitis B.
Tsai MS:
http://www.ncbi.nlm.nih.gov/pubmed?term=Tsai%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=22595393 , Chen JH:
http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=22595393 , Fang YW:
http://www.ncbi.nlm.nih.gov/pubmed?term=Fang%20YW%5BAuthor%5D&cauthor=true&cauthor_uid=22595393 , Yang AH:
http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20AH%5BAuthor%5D&cauthor=true&cauthor_uid=22595393 , Chang CH:
http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20CH%5BAuthor%5D&cauthor=true&cauthor_uid=22595393
Source
Division of Nephrology, Division of Gastroenterology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Department of Pathology, Veterans General Hospital-Taipei, and Department of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract
Interferon is used to treat chronic viral hepatitis because of low drug resistance and a high remission rate. However, its propensity to induce and modify autoimmunity has been reported. We used pegylated interferon ?-2a to treat a patient with chronic viral hepatitis B. After 5 months of this therapy, the patient developed membranous nephropathy. Complete remission of his nephrotic syndrome was achieved after 1 year of cyclosporine and corticosteroid therapy. During this same period, his chronic viral hepatitis B was controlled by entecavir. To our knowledge, this is the first case in which membranous nephropathy developed during pegylated interferon ?-2a therapy for chronic hepatitis B. The autoimmune modulation induced by interferon is the most likely mechanism for this complication.